Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP646163.RAWkL5ZGhoYhuYqKlNPaQ6bq6I6K017_QJCelQUltpvOQ130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646163.RAWkL5ZGhoYhuYqKlNPaQ6bq6I6K017_QJCelQUltpvOQ130_provenance.
• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151086.RABpzSBXmFIN6nwRpX8Rb2hTpR0y_9iJbpn9gwNtxVWJQ130_provenance.
• NP1151087.RApNXbcpk6_nj1mi0k80oM1aaSNGgFqPx6kQEO0Fny7rk130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151087.RApNXbcpk6_nj1mi0k80oM1aaSNGgFqPx6kQEO0Fny7rk130_provenance.
• NP646422.RA97rqB7JW0s8FLJixAxevWMAOLo1lVN1SG53yZ8cmoWQ130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646422.RA97rqB7JW0s8FLJixAxevWMAOLo1lVN1SG53yZ8cmoWQ130_provenance.
• NP1151088.RAPbB2tcaPFjEBbSDPOmPlnwvYPx2i2BIAWg17jxctmZU130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151088.RAPbB2tcaPFjEBbSDPOmPlnwvYPx2i2BIAWg17jxctmZU130_provenance.
• NP1151091.RA9zUbiSTqL-h2PqECGyTCPtMywaOhwzv8jKx4NJs31fM130_assertion description "[(a) ER?(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ER?(+) breast cancer with p53 dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151091.RA9zUbiSTqL-h2PqECGyTCPtMywaOhwzv8jKx4NJs31fM130_provenance.